Boundless Bio reports R&D pipeline progress

10 May 2025

US precision oncology company Boundless Bio (Nasdaq: BOLD) has announced financial results and business highlights for the fiscal quarter ended March 31, 2025.

Net loss totaled $15.8 million for the first quarter of 2025, compared to $15.4 for the same period in 2024. The company noted that its cash, cash equivalents, and short-term investments totaled $138.3 million as of March 31, 2025. Boundless’ share edged up 2% to $1.44 following the announcement.

The company also presented an update on its current research activities.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology